
Mount Sinai & LabCorp to Launch Digital Pathology Center
The center will implement a Philips pathology solution to improve patient care.
Photo/Thumb have been modified. Courtesy of
The Mount Sinai Health System and LabCorp
The organizations hope to improve laboratory services and patient care by implementing the Philips IntelliSite Pathology Solution. The product will enable digital pathology, which will be used to interpret genitourinary malignancies — mainly prostate tumors and head and neck cancers. According to the announcement, digital pathology will allow for real-time interpretations without the need for the pathologist to be on-site with the patient.
“Digital pathology gives us the unprecedented opportunity to expand our services to the community at large, and engage members of our department, considered key opinion leaders in their field, to provide expert diagnostic opinions in complex cases,” said Carlos Cordon-Cardo, M.D., Ph.D., chairman of the pathology, molecular and cell-based department at Mount Sinai Health System.
The Philips IntelliSite Pathology Solution is intended for in vitro diagnostic use as an aid for pathologists to view, review and diagnose digital images of stained slides. The solution is designed to improve the pathologist’s workflow and enable immediate access to consultations.
LabCorp will lead the integration of digital pathology into clinical practice across Mount Sinai’s hospitals. Mount Sinai pathologists, meanwhile, will provide consultations for cases interpreted by LabCorp’s specialty laboratory.
The Philips IntelliSite Pathology Solution will be deployed at Mount Sinai’s eight hospitals and certain ambulatory care locations.
“Digital pathology provides a unique opportunity to innovate laboratory pathology services and support pathologists in their daily practice,” said Marlon Thompson, general manager of Philips Digital & Computational Pathology.
Get the best insights in digital health
Related

















































